Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dedee F Murrell

Showing results (191-200 of 258) with videos related to

Pageof 26
Sort By:
Archives of Dermatology|June 23, 2010
Epidemiology of epidermolysis bullosa in the antipodes: the Australasian Epidermolysis Bullosa Registry with a focus on Herlitz junctional epidermolysis bullosaYong Chern Kho, Lesley M Rhodes, Susan J Robertson, et al.
Journal of the American Academy of Dermatology|December 3, 2023
The road to publication: Advice from journal editorsCristian Navarrete-Dechent, Karalikkattil T Ashique, John R Ingram, et al.
Orphanet Journal of Rare Diseases|June 25, 2020
Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study)Amy S Paller, John Browning, Milos Nikolic, et al.
Acta Dermato-Venereologica|September 10, 2008
Differential expression of pyloric atresia in junctional epidermolysis bullosa with ITGB4 mutations suggests that pyloric atresia is due to factors other than the mutations and not predictive of a poor outcome: three novel mutations and a review of the literatureNingning Dang, Sandra Klingberg, Adam I Rubin, et al.
Expert Opinion on Biological Therapy|January 7, 2022
Biological medication in atopic dermatitisRegina Fölster-Holst, Antonio Torrelo, Kinnor Das, et al.
The Journal of Dermatological Treatment|April 15, 2014
Age and etiology of childhood epidermolysis bullosa mortalityKam Lun Ellis Hon, Joshua J Li, Bernadette L Cheng, et al.
Orphanet Journal of Rare Diseases|January 5, 2020
The challenges of living with and managing epidermolysis bullosa: insights from patients and caregiversAnna L Bruckner, Michael Losow, Jayson Wisk, et al.
The Australasian Journal of Dermatology|April 2, 2015
Treatment of face and scalp solar (actinic) keratosis with daylight-mediated photodynamic therapy is possible throughout the year in Australia: Evidence from a clinical and meteorological studyLynda Spelman, Diana Rubel, Dedee F Murrell, et al.
Clinical and Experimental Dermatology|February 16, 2023
Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosisDedee F Murrell, Joyce M C Teng, Scott Guenthner, et al.
The Journal of Pathology|December 31, 2013
Flightless I over-expression impairs skin barrier development, function and recovery following skin blisteringZlatko Kopecki, Gink N Yang, Ruth M Arkell, et al.
Pageof 26

Showing results (191-200 of 258) with videos related to

Sort By:
Pageof 26
Archives of Dermatology|June 23, 2010
Epidemiology of epidermolysis bullosa in the antipodes: the Australasian Epidermolysis Bullosa Registry with a focus on Herlitz junctional epidermolysis bullosaYong Chern Kho, Lesley M Rhodes, Susan J Robertson, et al.
Journal of the American Academy of Dermatology|December 3, 2023
The road to publication: Advice from journal editorsCristian Navarrete-Dechent, Karalikkattil T Ashique, John R Ingram, et al.
Orphanet Journal of Rare Diseases|June 25, 2020
Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study)Amy S Paller, John Browning, Milos Nikolic, et al.
Acta Dermato-Venereologica|September 10, 2008
Differential expression of pyloric atresia in junctional epidermolysis bullosa with ITGB4 mutations suggests that pyloric atresia is due to factors other than the mutations and not predictive of a poor outcome: three novel mutations and a review of the literatureNingning Dang, Sandra Klingberg, Adam I Rubin, et al.
Expert Opinion on Biological Therapy|January 7, 2022
Biological medication in atopic dermatitisRegina Fölster-Holst, Antonio Torrelo, Kinnor Das, et al.
The Journal of Dermatological Treatment|April 15, 2014
Age and etiology of childhood epidermolysis bullosa mortalityKam Lun Ellis Hon, Joshua J Li, Bernadette L Cheng, et al.
Orphanet Journal of Rare Diseases|January 5, 2020
The challenges of living with and managing epidermolysis bullosa: insights from patients and caregiversAnna L Bruckner, Michael Losow, Jayson Wisk, et al.
The Australasian Journal of Dermatology|April 2, 2015
Treatment of face and scalp solar (actinic) keratosis with daylight-mediated photodynamic therapy is possible throughout the year in Australia: Evidence from a clinical and meteorological studyLynda Spelman, Diana Rubel, Dedee F Murrell, et al.
Clinical and Experimental Dermatology|February 16, 2023
Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosisDedee F Murrell, Joyce M C Teng, Scott Guenthner, et al.
The Journal of Pathology|December 31, 2013
Flightless I over-expression impairs skin barrier development, function and recovery following skin blisteringZlatko Kopecki, Gink N Yang, Ruth M Arkell, et al.
Pageof 26